Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the ...

在其他近期新闻中，Biodexa Pharmaceuticals PLC已任命Precision for Medicine, ...

Biodexa Pharmaceuticals (BDRX) announced the results of its Type C meeting with the U.S. Food and Drug Administration, FDA, regarding the ...

Biodexa Pharmaceuticals announced a successful Type C meeting with the FDA, which has cleared the way to finalize the Phase 3 protocol for its drug eRapa in treating familial adenomatous polyposis ...

The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in FAP at six months at Digestive Disease Week in May 2024 and 12 months data ...

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S.

美国食品药品监督管理局 (FDA) 已授予雷帕霉素胶囊 eRapa 快速通道资格，用于治疗家族性腺瘤性息肉病 (FAP)。 目前，FDA 尚未 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous ...

February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or ...

Detailed price information for Biodexa Pharmaceuticals Plc ADR (BDRX-Q) from The Globe and Mail including charting and trades.